A Look at Veliparib Plus Chemotherapy for First-Line Treatment of Advanced NSCLC

TIL Therapy Endures for Carefully Selected Patients: A Q&A with Dr. Benjamin C. Creelan

Optimal Pathologic Staging of Lung Cancer Depends on More Than the Pathologist

Early Palliative Care: A European Perspective

As Treatment Options in Lung Cancer Have Expanded, so Have Costs

Small, High PLCG2-Expressing Intratumoral Cells May Drive Metastasis

COAST Data Support Further Research of Immunotherapy Combinations

Alternative Dosing Strategies for Immune Checkpoint Inhibitors

Panel Explores Emerging Treatments and Sequencing Strategies for Patients with Advanced NSCLCs Driven by Rare Oncogenes

Evidence Supports Adding Biological, Pathological, and Molecular Assessments to the TNM Lung Cancer Staging System

Real-World Data from Taiwan Shows Stage Shift Has Improved Lung Cancer Survival Rates

Using Comparative Effectiveness Data Based on Non-Randomized Study Designs to Support Regulatory, Reimbursement Decision-Making